Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
Submission of Matters to a Vote of Security
Holders.
Ohr Pharmaceutical, Inc., a Delaware corporation (the Company),
held its 2017 Annual Meeting of Stockholders (the 2017 Annual
Meeting) on April 14, 2017. There were 35,961,396 shares of
common stock entitled to be voted, of which 23,263,677 were voted
in person or by proxy. The following matters were submitted to a
vote of the Companys stockholders at the 2017 Annual Meeting.
Proposal 1.
A proposal to elect two class I directors to serve until the 2020
Annual Meeting of Stockholders and until their successors are
elected and qualified or until death, resignation or removal. The
nominees, June Almenoff and Thomas Riedhammer, were elected to
serve as class I directors. The results of the voting were as
follows:
| Nominees | Votes For | Withheld | Broker Non-Votes | |||
| June Almenoff | 5,574,557 | 163,730 | 17,525,390 | |||
| Thomas Riedhammer | 5,540,229 | 198,058 | 17,525,390 |
Proposal 2.
A proposal to approve a non-binding advisory resolution on
executive compensation. The proposal was approved and results of
the voting were as follows:
| For | Against | Abstentions | BrokerNon-Votes | |||
| 5,243,697 | 410,703 | 83,887 | 17,525,390 |
Proposal 3.
A proposal to ratify the selection of MaloneBailey, LLP as the
Companys independent auditors for the 2017 fiscal year. The
proposal was ratified and the results of the voting were as
follows:
| For | Against | Abstentions | BrokerNon-Votes | |||
| 21,815,457 | 1,285,700 | 162,520 |
About Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)
Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company’s animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin. It also owns various other compounds in earlier stages of development, including the PTP1b inhibitor Trodusquemine and related analogs. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) Recent Trading Information
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) closed its last trading session down -0.052 at 0.780 with 4,528,149 shares trading hands.
